Literature DB >> 3744381

Chimeric antibodies with 17-1A-derived variable and human constant regions.

L K Sun, P Curtis, E Rakowicz-Szulczynska, J Ghrayeb, S L Morrison, N Chang, H Koprowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3744381

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


× No keyword cloud information.
  7 in total

1.  Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

Authors:  G Masucci; P Ragnhammar; P Wersäll; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

Authors:  A Y Liu; R R Robinson; K E Hellström; E D Murray; C P Chang; I Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

4.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

Authors:  J Fagerberg; J E Frödin; P Ragnhammar; M Steinitz; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

5.  Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Authors:  P Ragnhammar; J Fagerberg; J E Frödin; P Wersäll; L O Hansson; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

6.  Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.

Authors:  P Ragnhammar; J E Frödin; P P Trotta; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

7.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.